Gradalis
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2545 Golden Bear Dr Ste 110, Carrollton,...Phone Number
(214) 442-8100Website
www.gradalisinc.comRevenue
$8.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
8
1
1
1
1
About Gradalis
Gradalis is a late-stage clinical biotechnology company developing immunotherapies for multiple cancer indications including an upcoming Phase 3 registration trial in patients with ovarian cancer. The company's proprietary bi-shRNA therapy platform, which has been proven in its clinical studies, can be utilized to silence a broad range of genes and is applicable to multiple cancer types.Explore more
Gradalis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gradalis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Gradalis recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Gradalis
Check out if Gradalis is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Gradalis has new funding data
Gradalis, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Gradalis had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Gradalis launches new products
Check if Gradalis has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Gradalis
Compare insights from companies similar to Gradalis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Gradalis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gradalis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gradalis.
Gradalis Tech Stack
A closer look at the technologies used by Gradalis
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Gradalis News & Media
Gradalis Appoints Steven D. Weinstein as Chief Executive Officer
DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, today announced the appointment of Steven D. Weinstein as Chief Executive Officer. Mr. Weinstein brings more than two decades of experience in life sciences leadership, venture capital, and company building. He has a proven track record of guiding innovative healthcare organizations from early-stage development through commercialization with experience sGradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden
DALLAS, March 14, 2025 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage biotechnology company focused on personalized anti-cancer therapy for patients with ovarian and other cancers, announced a peer-reviewed publication in Scientific Reports. The paper details the methods and validation of Gradalis’ exome sequencing procedure and associated bioinformatics pipeline for identifying signal patterns that drive cancer growth and spread. Titled “Exome sequencing shows same pattern of clonal tumorGradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil® (Gemogenovatucel-T): An Investigational Personalized Immunotherapy for Advanced Ovarian Cancer
Recognizing clinical evidence from the Phase 2b VITAL Study of Vigil in homologous recombination proficient (HRP) patients with high clonal tumor mutation burden (cTMB-H)Gradalis Announces Peer-Reviewed Publication Demonstrating Potential of Novel 3D Scaffold Tissue Technology to Expand Vigil Platform
DALLAS, June 06, 2023 (GLOBE NEWSWIRE) -- Gradalis Inc. announced the peer-reviewed publication in Advanced NanoBioMed, highlighting the therapeutic applications of a new extracellular matrix platform developed for tumor cell expansion in collaboration with the University of Michigan Biointerfaces Institute. The publication entitled, “A Scalable Engineered Extracellular Matrix Platform to Expand Tumor Cells,” provides proof of principle for a large-scale three-dimensional (3D) platform that is d
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gradalis
Sign Up For FreeTo access detailed company insights
Gradalis is a late-stage clinical biotechnology company developing immunotherapies for multiple cancer indications including an upcoming Phase 3 registration trial in patients with ovarian cancer. The company's proprietary bi-shRNA therapy platform, which has been proven in its clinical studies, can be utilized to silence a broad range of genes and... Read More
